Cannabis Law Report

AUGUST 2, 2021

It’s time for your Daily Hit of cannabis financial news for August 2, 2021. CSE: JUSH) (OTCQX: JUSHF) decided to jump the gun with its good news and pre-announced its second-quarter 2021 financial results. million in 2021. The post The Daily Hit: August 2, 2021 appeared first on Green Market Report. On the Site.

Research and Development 111

Research and Development Data Access Medicine 111

Cannabis Law Report

AUGUST 10, 2021

The Federal Court of Appeals in Canada ratified a Ministry of Health decision to refuse to provide J anssen Pharmaceuticals, a subsidiary of Johnson and Johnson (NYSE: JNJ ), data protection for Spravato, a ketamine analog approved for depression. What Is Data Protection And Why Is It Important? and Canada. What Happened?

Data 98

Data Pharmaceutical Treatment Medicine 98

Cannabis Law Report

MAY 10, 2022

More than half of all prescriptions for medicinal cannabis in Australia are written by doctors in Queensland, with prescriptions often given for conditions there is little evidence medicinal cannabis can treat, new research reveals. Queensland was the source of 51% of prescriptions between 2016 and 2021.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

OCTOBER 28, 2021

Psymposia report… O n Sep 23, 2021, Psymposia staff received an email from the personal email account of Mark Haden — the former Executive Director of psychedelic nonprofit MAPS Canada and current Director of Clinical Trials for Psygen Inc. MAPS Canada’s Data Breach Foreshadows Corporadelic Future. Read full report.

Data 52

Data Clinical Trials Events Medicine 52

Cannabis Law Report

APRIL 5, 2021

BASEL, Switzerland, April 5, 2021 /CNW/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech… Read More.

Data 87

Data Medicine Cannabis 87

Cannabis Law Report

DECEMBER 8, 2021

DUBLIN–(BUSINESS WIRE)–The “Global Psychiatry Partnering 2014-2021: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering. Access to headline, upfront, milestone and royalty data. Access Psychiatry deal headline, upfront, milestone and royalty data.

Access 52

Access Data Pharmaceutical Research and Development 52

Cannabis Law Report

AUGUST 24, 2022

Results from the third Cannabis as Medicine study. The third Cannabis as Medicine Survey (CAMS20) follows on from CAMS16 and CAMS18, and includes 1,600 people using medical cannabis between September 2020 and January 2021. More work is required to enhance health provider education regarding medicinal cannabis.

Medicine 52

Medicine Legalization Chronic Pain Access 52

The Cannigma

JANUARY 16, 2021

When you walk into a hardware store, pharmacy, or even a liquor store, if you don’t know exactly what product will meet your needs there’s someone educated enough to point you to the right product and the data to back up that recommendation, says Tyler Dautrich, COO of Releaf.

Data 100

Data Research and Development Patients Strains 100

Cannabis Law Report

JUNE 14, 2021

June 7, 2021 – June 11, 2021. M ind Medicine Inc. Machine-Learning (“ML”) (sometimes referred to as artificial intelligence or “AI”) has experienced a renaissance over the past five years thanks to a combination of big data, fast processors, and new algorithms. Market Performance. Powered by. CFN Enterprises Inc.

Research and Development 66

Research and Development Data Retail Programs 66

Cannabis Law Report

NOVEMBER 29, 2021

State legislators in 2021 enacted over 50 laws liberalizing marijuana policies in more than 25 states, according to a report issued today by the National Organization of the Reform of Marijuana Laws (NORML). 2021 was a significant year for marijuana policy reform. The law took effect on July 1, 2021. FULL REPORT. New Jersey.

Legislation 98

Legislation Patients Retail Access 98

The Cannigma

JUNE 30, 2021

On July 1st, 2021, new cannabis legalization are going into effect in Connecticut, New Mexico, and Virginia, just a couple days after a recreational cannabis legalization measure went into effect in South Dakota. As of July 1, 2021, all five states had both adult-use and medical cannabis programs. ? Spasms 4,937 21.9% PTSD 3,440 15.2%

Chronic Pain 137

Chronic Pain Marijuana Conditions Patients 137

Cannabis Law Report

AUGUST 23, 2021

Medicinal Cannabis Access Data Dashboard. 19 August 2021. To improve transparency and data accessibility, the TGA publishes de-identified data on the number of unapproved medicinal cannabis products accessed through the Special Access Scheme (SAS). Medicinal cannabis Special Access Scheme category B data.

Data 105

Data Access Medicine Patients 105

Cannabis Law Report

AUGUST 19, 2021

DUBLIN–(BUSINESS WIRE)–The “Global Industrial Hemp Market Report and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. between 2021 and 2026 to reach a value of USD 14.6 12 Trade Data Analysis (HS Code: 5302). The global industrial hemp market attained a value of USD 4.7

Hemp 98

Hemp Research and Development Pharmaceutical Data 98

Cannabis Law Report

JULY 20, 2021

Rahn & Associates announced today that it launched new risk management solutions for the burgeoning psychedelic medicinal industry. With our new psychedelic medicinal insurance solutions, business can access the necessary coverages to protect their business, attract qualified officers/directors, and bring new treatments to market.”.

Medicine 98

Medicine Business Research and Development Chronic Pain 98

Cannabis Law Report

NOVEMBER 29, 2021

It has been shown that medicinal marijuana may help alleviate the symptoms of some conditions, provided that doctors keep a close eye on how much is taken and how often it’s used. Nevertheless, there have been several testimonies from medicinal marijuana users, yet some Americans remain skeptical. .

Legalization 52

Legalization Research and Development Decriminalization Marijuana 52

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “In

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

TheAnswerPage

JUNE 24, 2021

What has been the most common mode of administration of cannabinoid-based medicines (CBMs) in RCTs examining the efficacy of CBMs to treat pain? 2021 May;20(5):21-23, 28-33 | doi:10.12788/cp.0121, 2021 May;20(5):21-23, 28-33 | doi:10.12788/cp.0121, ” MDedge Psychiatry, 3 May 2021, [link]. Current Psychiatry.

Cannabinoids 52

Cannabinoids Data Medicine 52

Cannabis Law Report

NOVEMBER 18, 2021

The first iteration of the Global Drug Policy Index was released in November 2021, and it evaluates the performance of 30 countries covering all regions of the world, for the year 2020. The 2021 edition of the Index covers 30 countries from all regions of the world. Each country is then given a total score ranging from 0 to 100.

Policy 52

Policy Data Media Access 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.)

CBD 144

CBD Seed-To-Sale Food Access 144

The Blunt Truth

MAY 6, 2021

A bipartisan, bicameral group recently introduced the VA Medicinal Cannabis Research Act. Also this week, another bipartisan, bicameral group introduced the Marijuana Data Collection Act. This bill directs the Department of Veterans Affairs to conduct research into the efficacy of medical marijuana in treating veterans with PTSD.

Decriminalization 111

Decriminalization State Laws Collective CBD 111

Medical Marijuana Program Connection

JANUARY 10, 2024

.–(BUSINESS WIRE)–Beginning in January 2024, natural medicine research nonprofits Realm of Caring, Unlimited Sciences and Lily’s Lighthouse will collaborate to collect data for an observational study on the efficacy of functional mushrooms in treating epilepsy. Read More

Epilepsy 52

Epilepsy Collective Data Medicine 52

Cannabis Law Report

AUGUST 23, 2021

& Notice of 2021 Final Results. . After confirmation of 6-months stability of tech-transfer batch, the work has been initiated, with preliminary data packages available by the second half of September, well within the proposed timelines. Pre-Close Trading Update; US OTC QB Market Application. &

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

AUGUST 26, 2021

California collected about $817 million in adult-use marijuana tax revenue during the 2020-2021 fiscal year, state officials estimated on Monday. August 23, 2021. Annual Report on Tax Exemptions for Medicinal Cannabis [Publication Details]. Annual Report on Tax Exemptions for Medicinal Cannabis [Publication Details].

Medicine 105

Medicine Marijuana Retail Cultivation 105

Cannabis Law Report

JUNE 8, 2021

In addition to the report, which includes maps and overviews, you’ll obtain invaluable data from our extensive database that covers areas such as consumption, licensing and production as well as current legal proposals. CBD Regulated as Medicine. Key Topics Covered: Introduction. Medical Cannabis. Recreational Cannabis.

Recreational 98

Recreational Data Environment Topical 98

Veriheal

NOVEMBER 22, 2021

Have you ever wondered who spends more on cannabis: those who consume recreationally or for medicinal purposes? Headset , a leading cannabis data and market intelligence platform, recently conducted an audit of cannabis sales data around the United States—and the discoveries were interesting. Well, we’ve got answers.

Recreational 98

Recreational Data Dispensary Cannabis 98

Cannabis Law Report

SEPTEMBER 28, 2021

The data will then be analysed to recognise trends in responses. • Participants: The survey is open to all ACT residents over 18 years. • Use of Data and Feedback: The data will be used in my ANIP thesis and possibly for future research. My ANIP host organisation (Johnathan Davis MLA’s office) may also use the data.

Therapy 52

Therapy Medicine Data Collective 52

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Watch how Supera-CBD works. “We

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

JULY 13, 2021

As the psychedelic renaissance contributes to a swelling pool of safety and efficacy data pertaining to the potential therapeutic benefits of psychedelic medicine, many localities—particularly in North America—are revising their legal frameworks. Last updated: July 4th, 2021. This is what they are saying.

Decriminalization 105

Decriminalization Legalization Data Safety 105

Veriheal

OCTOBER 6, 2023

Additionally, rescheduling would mean that millions of individuals living in states without legalization would still have no way of accessing the medicine they need. private health insurance financial data from 2010 to 2021. The data was provided by the National Association of Insurance Commissioners.

Data 113

Data Decriminalization Extraction Legalization 113

Cannabis Law Report

JUNE 1, 2021

TORONTO, June 01, 2021 (GLOBE NEWSWIRE) — via InvestorWire – RYAH Group, Inc. We are pleased to bring RYAH’s IoT device and integrated data solutions to the United Kingdom, providing a new level of session accuracy, patient feedback consistency, and data integrity to the clinical framework in plant-based medicine research.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JUNE 24, 2021

DUBLIN–(BUSINESS WIRE)–The “Global Cannabidiol Market (2021-2026) by Source, Distribution Channel, Product, Route of Administration, End-user, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. ABcann Medicinals, Inc.

Research and Development 78

Research and Development Tincture Chronic Pain Pharmaceutical 78

Cannabis Law Report

OCTOBER 24, 2021

What used to be considered an illicit drug in most countries is now a decriminalized plant with some medicinal potential. Medicinal: Health Canada continues to regulate the process for the medicinal sale of Cannabis in Canada. At least until there is more historical data and the market landscape normalizes (whatever normal is).

Strains 52

Strains Edibles Extraction Vaping 52

Cannabis Law Report

OCTOBER 30, 2019

Despite strong prescription growth in Australia and inroads in many jurisdictions abroad, not to mention recreational cannabis legalisation in Canberra which paradoxically may be a threat to the sector , weak investor sentiment has been a tough pill to swallow for medicinal cannabis companies on the ASX.

Medicine 45

Medicine Wellness and Beauty Research and Development Patients 45

Cannabis Law Report

SEPTEMBER 29, 2021

(CSE: CANN) (OTCQX: HERTF) ( “Heritage ” or the “Company ”), today announced its financial results as at and for the three- and nine-month periods ended July 31, 2021 (“ Q3 2021 ”). Key Financial Highlights of Fiscal Q3 2021. million in the third quarter of 2021, an increase of $2.7 Gross profit in Q3 2021 was $1.2

Concentrates 52

Concentrates Events Cannabis Vaping 52

TheAnswerPage

MAY 28, 2022

What has been the most common mode of administration of cannabinoid-based medicines (CBMs) in randomized control trials (RCTs) examining the efficacy of CBMs to treat pain? 2021 May;20(5):21-23, 28-33 | doi:10.12788/cp.0121, MDedge Psychiatry, 3 May 2021, www.mdedge.com/psychiatry/article/239193/pain/cannabinoid-based-medications-pain.

Cannabinoids 52

Cannabinoids Data Medicine 52

Cannabis Law Report

JULY 19, 2021

First-of-its-kind universal milliliter to milligram calculation has potential to transform rapidly growing plant-based medicines sector. July 19, 2021 07:58 ET | Source: Potbotics, Inc. Toronto, July 19, 2021 (GLOBE NEWSWIRE) — via InvestorWire — RYAH Group, Inc. billion by 2027. About RYAH Group, Inc.

Therapy 76

Therapy Data Research and Development Events 76